Showing results (811-820 of 2,331) with videos related to
Sort By:
Pageof 234
Clinical Drug Investigation|August 1, 2008
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic studyJohn K Darby, David J Pasta, Michael G Wilson, et al.Clinical Drug Investigation|November 11, 2008
Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional studyPhilippe Denis, Antoine Lafuma, Viviane Jeanbat, et al.Clinical Drug Investigation|November 11, 2008
Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled studyOlcay Gursoy, Dilek Memiş, Necdet SutClinical Drug Investigation|November 11, 2008
Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre studyMona Darwish, Edward T Hellriegel, Fang XieClinical Drug Investigation|March 16, 2007
Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipientsMasatomo Miura, Kazuyuki Inoue, Shigeru Satoh, et al.Clinical Drug Investigation|March 16, 2007
Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass indexKatarina Raslová, Soren Can Tamer, Per Clauson, et al.Clinical Drug Investigation|May 18, 2007
Delapril plus indapamide: a review of the combination in the treatment of hypertensionLuca Cavalieri, Giovanni CremonesiClinical Drug Investigation|August 12, 2020
Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?Bruno Charpiat, Nathalie Bleyzac, Michel TodClinical Drug Investigation|August 12, 2020
Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims DatabaseNajat J Ziyadeh, Anja Geldhof, Wim Noël, et al.Clinical Drug Investigation|April 20, 2023
Optimising Decision Making in Chronic Venous Disease Management with Micronised Purified Flavonoid FractionJorge H UlloaPageof 234